🇺🇸 FDA

Intelligence Platform

Patents

Browse 71 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11760764

Methods and compositions for targeting PD-L1

Aligos Therapeutics, Inc. · Granted Tue Sep 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11760761

Methods and compositions for targeting PD-L1

Aligos Therapeutics, Inc. · Granted Tue Sep 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11746152

Methods of cancer treatment and therapy using a combination of antibodies that bind glycos

The Board of Regents of the University of Texas System · Granted Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11718679

CD137 antibodies and PD-1 antagonists and uses thereof

Compass Therapeutics LLC · Granted Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11713353

Single-domain antibodies and variants thereof against PD-1

Nanjing Legend Biotech Co., Ltd · Granted Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11685918

Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11685775

Method of increasing the ratio of effector T cells to regulatory T cells in a tumor by adm

The Regents of the University of California · Granted Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11673954

Single-domain antibodies and variants thereof against PD-L1

Nanjing Legend Biotech Co., Ltd · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11661455

Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety

Orionis Biosciences, Inc · Granted Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11660352

Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof

The Board of Regents of the University of Texas System · Granted Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11566076

Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

Five Prime Therapeutics, Inc. · Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11542312

IL-2 superagonists in combination with anti-PD-1 antibodies

Medicenna Therapeutics Inc. · Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11525002

Human PD-L1 antibodies and methods of use therefor

The Board of Regents of the University of Texas System · Granted Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11505600

Methods of treating skin cancer by administering a PD-1 inhibitor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11498966

PD-1 and PD-L1 binding agents

Orionis Biosciences, Inc · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11497734

Dual inhibitors of TIM-3 and PD-1 pathways

Aurigene Discovery Technologies Limited · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11464795

Saponin compound targeting PD-1 and application thereof

East China University of Science and Technology · Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11421034

Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

Five Prime Therapeutics, Inc. · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11357842

PD-L1 targeting DNA vaccine for cancer immunotherapy

Vaximm AG · Granted Tue Jun 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11324822

Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer

Syndax Pharmaceuticals, Inc. · Granted Tue May 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11292842

Anti-PD-1 antibodies for treatment of lung cancer

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11254746

Anti-PD-1 monoclonal antibody, and preparation method therefor and application thereof

SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11254752

Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibo

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11141434

Programmed death 1 ligand 1 (PD-L1) binding proteins and methods of use thereof

Iovance Biotherapeutics, Inc. · Granted Tue Oct 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted